The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Year: 2014
Type: article
Source: Molecular Cancer Therapeutics
Institution: Eli Lilly (United States)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W2166229764
